# Vivian Y. Shi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/vivian-y-shi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 5,600 |
| Field | Hidradenitis Suppurativa and Treatments |
| h-index | 40 |
| i10-index | 136 |
| Last Known Institution | University of Washington |
| OpenAlex ID | https://openalex.org/A5002888235 |
| ORCID iD | 0000-0002-7510-9428 |
| Works | 413 |

## Researcher papers

- [Natural Oils for Skin-Barrier Repair: Ancient Compounds Now Backed by Modern Science](https://scholariq.org/papers/natural-oils-for-skin-barrier-repair-ancient-compounds-now-backed-by-modern/)
- [The Skin Barrier and Moisturization: Function, Disruption, and Mechanisms of Repair](https://scholariq.org/papers/the-skin-barrier-and-moisturization-function-disruption-and-mechanisms-of-repair/)
- [Role of sebaceous glands in inflammatory dermatoses](https://scholariq.org/papers/role-of-sebaceous-glands-in-inflammatory-dermatoses/)
- [Epithelial barrier dysfunctions in atopic dermatitis: a skin-gut-lung model linking microbiome alteration and immune dysregulation](https://scholariq.org/papers/epithelial-barrier-dysfunctions-in-atopic-dermatitis-a-skin-gut-lung-model/)
- [A Comparison of International Management Guidelines for Hidradenitis Suppurativa](https://scholariq.org/papers/a-comparison-of-international-management-guidelines-for-hidradenitis-suppurativa/)
- [COVID-19 and immunomodulator/immunosuppressant use in dermatology](https://scholariq.org/papers/covid-19-and-immunomodulator-immunosuppressant-use-in-dermatology/)
- [Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)](https://scholariq.org/papers/phase-3-efficacy-and-safety-of-abrocitinib-in-adults-with-moderate-to-severe/)
- [The impact of airborne pollution on atopic dermatitis: a literature review](https://scholariq.org/papers/the-impact-of-airborne-pollution-on-atopic-dermatitis-a-literature-review/)
- [The impact of stress on epidermal barrier function: an evidence‐based review](https://scholariq.org/papers/the-impact-of-stress-on-epidermal-barrier-function-an-evidence-based-review/)
- [The <scp>pan‐JAK</scp> inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase <scp>IIb</scp> trial*](https://scholariq.org/papers/the-scp-pan-jak-scp-inhibitor-delgocitinib-in-a-cream-formulation-demonstrates/)
- [Insights From Caregivers on the Impact of Pediatric Atopic Dermatitis on Families: “I’m Tired, Overwhelmed, and Feel Like I’m Failing as a Mother”](https://scholariq.org/papers/insights-from-caregivers-on-the-impact-of-pediatric-atopic-dermatitis-on/)

## Researcher topics

- [Hidradenitis Suppurativa and Treatments](https://scholariq.org/topics/hidradenitis-suppurativa-and-treatments/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Colorectal and Anal Carcinomas](https://scholariq.org/topics/colorectal-and-anal-carcinomas/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)
- [Acne and Rosacea Treatments and Effects](https://scholariq.org/topics/acne-and-rosacea-treatments-and-effects/)

## Researcher university

- [University of Washington](https://scholariq.org/institutions/university-of-washington/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.